Iveric bio the latest to be hit by COVID-19 as it delays a key trial

Iveric Bio has been forced to hit the pause button for a pivotal test on its leading drug Zimura as COVID-19 continues to back up clinical trials.

The biotech said it was now having to delay enrollment in the second pivotal study for its investigational therapy Zimura, which was slated to be trialed in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).